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Background: Glioblastomas are the most common central nervous system neoplasia in adults, with 9,000 cases in
the US annually. Glioblastoma multiformae, the most aggressive glioma subtype, has an 18% one-year survival rate,
and 3% two year survival rate. Recent work has highlighted the role of the transcription factor RE1 Silencing
Transcription Factor, REST in glioblastoma but how REST function correlates with disease outcome has not been
described.
Method: Using a bioinformatic approach and mining of publicly available microarray datasets, we describe an
aggressive subtype of gliomas defined by a gene signature derived from REST. Using this REST gene signature we
predict that REST function is enhanced in advanced glioblastoma. We compare disease outcomes between tumors
based on REST status and treatment regimen, and describe downstream targets of REST that may contribute to the
decreased benefits observed with high dose chemotherapy in REM tumors.
Results: We present human data showing that patients with “REST Enhanced Malignancies” (REM) tumors present
with a shorter disease free survival compared to non-REM gliomas. Importantly, REM tumors are refractory to
multiple rounds of chemotherapy and patients fail to respond to this line of treatment.
Conclusions: This report is the first to describe a REST gene signature that predicts response to multiple rounds of
chemotherapy, the mainline therapy for this disease. The REST gene signature may have important clinical
implications for the treatment of glioblastoma.
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RE1-silencing transcription factor (REST) is a transcrip-
tional repressor that regulates the expression of approxi-
mately 2,000 neuronal genes in neural and non-neural
tissues, including embryonic and neural stem cells (NSC)
[1-4]. In development, loss of REST function is an integral
step in NSC differentiation, and inappropriate maintenance
of REST function has been found to prevent differentiation
of NSC into neurons [4-6]. In neoplasia, heightened REST
function in medulloblastoma tumor cells contributes to
their tumorigenicity in mouse models of the disease, in part* Correspondence: asroopra@wisc.edu
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distribution, and reproduction in any mediumby preventing their differentiation [7,8]. Accordingly, many
human medulloblastoma tumors show significantly higher
REST protein levels than adjacent normal brain tissue.
Increased REST levels also correlated with lower overall
and event-free survival [9].
Glioblastomas are the most common central nervous
system neoplasia in adults, with 9,000 cases in the US an-
nually. Regardless of whether gliomas arise from astrocytes
(astrocytomas) or oligodendrocytes (oligodendromas), they
carry with them a uniformly poor prognosis. Glioblastoma
multiformae, the most aggressive glioma subtype, has an
18% one-year survival rate, and 3% two-year survival rate
[10]. Recently, a role for REST was suggested in glioma
with REST up-regulation able to drive cell proliferation and
suppress differentiation [11,12]. Elegant work from Conti
et al and Kamal et al showed increased REST protein inCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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knockdown of REST in glioblastoma cell lines reduced
proliferation rate and promoted differentiation. How-
ever, how REST levels corresponded to patient outcome
was not described. In this work, we will describe an ag-
gressive subtype of gliomas with enhanced REST func-
tion, termed REST Enhanced Malignancies (REM). We
compare disease outcomes between tumors based on
REST status and treatment regimen, and describe down-
stream targets of REST that may contribute to the
decreased benefits observed with high dose chemother-
apy in REM tumors.Figure 1 Expression of REST signature genes in glioma tumors and n
are compared between 176 glioma tumors and non-neoplastic brain tissue
shows significantly greater REST target gene expression than many of the o
REST target genes is displayed below as mean +/- standard error. Oligoden
expression with increasing tumor grade. All heatmaps and tumor analysesResults and discussion
To evaluate REST function in gliomas we utilized a 24-gene
REST gene signature which has been demonstrated to be a
reliable reporter of REST function in tumors [13]. Using
this gene signature, we evaluated REST function in a data-
set of 176 neural tissue samples, including non-neoplastic
brain tissue as well as oligodendromas and astrocytomas of
varying grades (Figure 1) [14]. Both the oligodendromas
and astrocytomas showed a statistically significant decrease
in REST target gene expression with respect to their non-
neoplastic counterparts. Intriguingly, both glioma subtypes
showed significant decreases in mean REST target geneon-neoplastic brain tissue. Expression REST signature genes (y-axis)
s (x-axis) from NCBI dataset GSE4290. Non-neoplastic brain tissue
ligodendroma and astrocytomas. Average expression of normalized
dromas and astrocytomas both show decreased REST target gene
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Figure 2 GSEA comparing REST target gene expression in glioma tumors and non-neoplastic brain. Gene set enrichment analysis results
are shown comparing gene expression between 176 glioma tumors (of varying grade and type) and non-neoplastic brain (NCBI Dataset number
GSE4290) over 3 independent lists of REST target genes. These results suggest that when compared to normal brain tissue, the glioma tumors
in this dataset show a robust down-regulation of REST target genes. The FDR q-value and nominal p-value for each genelist suggest that such an
enrichment of REST target gene expression in non-neoplastic tumors is unlikely to occur by random chance. GSEA was performed using 1,000
permutations utilizing a weighted enrichment statistic and a Signal2Noise metric for ranking genes. Genes with multiple probes were collapsed
into a single gene using the max-probe value. The REST signature genelist is comprised of 24 genes that all contain REST binding sites and
responded to REST knockdown with at least a two-fold up-regulation of target mRNA in three different cell lines, as previously described
(Wagoner et al. 2010). The expanded REST genelist contains an additional 30 REST target genes that are up-regulated at least two-fold with loss
of REST function in two of three cell lines. The 971 REST ChIP-Seq genes were determined by ChIP-Seq analysis from Jurkat t-cells by Johnson
et al [3].
Figure 3 High grade gliomas have varying levels of REST target gene expression. Grades III and IV gliomas from NCBI Dataset GSE4271
were broken into groups expressing high and low levels of REST signature genes (termed near-normal and REM tumors, respectively) using
self-organizing maps and a euclidian distance metric. (A) Heatmap of REST signature gene expression for the 100 high-grade glioma tumors.
(B) GSEA was used to determine if the differences in expression of REST target genes between REM and near-normal tumors are statistically
significant. These results suggest that REM tumors indeed show significantly depleted expression of a wide range of REST target genes. GSEA
parameters and genesets were utilized as in Figure 2.
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Figure 4 Neuronal markers do not segregate with REM or near-normal tumors. (A) Box plot of neuronal markers derived from dataset
GSE9566, which profiles genes expressed in pure populations of astrocytes, oligodendrocytes and neurons (Cahoy, Emery et al. 2008). Genes that
were selectively expressed in neurons (p<10-15) were filtered out if they contained a consensus REST binding site within 30kb of the gene, or if
REST had been published to bind the gene in ChIP-ChIP or ChIP-Seq experiments [3,17]. Top, middle, and bottom lines of the box plot represent
75th, 50th and 25th percentile samples, respectively. The top and bottom whiskers represent 90th and 10th percentile samples, respectively.
(B) Heatmap showing expression of neuronal markers in REM and near-normal tumors from gliomas in dataset GSE4271. Neither REM nor
near-normal tumors show significant enrichment for non-REST associated neuronal markers. (C) Neither REM, Mid-, or Near Normal subtypes show
a significant concerted increase in all non-REST target neuronal markers suggesting equal levels of neuronal involvement in the tumor.
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http://www.biomedcentral.com/1471-2164/13/686expression with increasing tumor grade, suggesting that
heightened REST function may be associated with more ag-
gressive disease. We also evaluated REST function in these
tumors using gene set enrichment analysis (GSEA), which
measures the relative enrichment of a given geneset in one
tumor population over another in a statistically rigorous
manner [15]. Using GSEA, we compared REST function in
gliomas and non-neoplastic brain tissue using 3 independ-
ent lists of REST target genes (Figure 2). GSEA found that
the genes in the REST 24-gene signature were indeed
down-regulated in a statistically significant manner in a
subset of gliomas (p<0.05, FDR q-val<0.05). A second gene
list examining 30 REST target genes not present in the 24-
gene signature that were induced at least 2-fold in at least 2Figure 5 Glioma Copy Number Variation In Chromosome 4q12. Segm
events representing 141 glioma tumors (y-axis). Exons for known genes are
between boxes. The glioma oncogene PDGFRA is the focus of 4q12 amplifof three cell lines tested in Wagoner et al [13] was also
strongly under-expressed in the same subset of gliomas.
This suggests that enhanced REST is not limited to a small
set of REST target genes (p<0.001, FDR q-val<0.01). Finally,
GSEA was performed based on a geneset comprised of over
800 REST target genes identified in Jurkat T-cells as REST
targets by ChIP-Seq after removal of the 24-gene signature
(p<0.001, FDR q-val<0.01) [3]. This analysis confirms the
statistically significant down-regulation of REST target
genes in gliomas with respect to non-neoplastic tissue, sug-
gesting an increase in REST function in the tumors.
Intriguingly, the increased REST function observed in gli-
omas was not uniform across all tumors, with some tumors
expressing REST target genes near the levels observed inentation analysis depicts 4q12 (x-axis) amplification and deletion
highlighted as blue boxes, with introns depicted as blue lines
ication, consistent with what is normally seen in the literature.
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moral variation of REST function is significant, we ranked
tumors by expression of the 24-gene signature and then
divided gliomas into groups of high and low expression of
REST signature genes. Tumors with low level expression of
genes in the REST signature were termed REST enhanced
malignancies (REM), and those with expression levels of
REST target genes at or near that of normal, non-
neoplastic tissue were termed “near-normal” tumors
(Figure 3A). Using the above three independent REST gene
lists, GSEA found statistically significant decreases in REST
target gene mRNA levels, suggesting that a significant
population of these high grade gliomas have heightened
REST function (Figure 3B).
Given that many REST target genes are highly expressed
in mature neurons, one possible explanation for the ele-
vated REST function observed in REM tumors could be
that those tumors have low levels of neuronal involvement
or “neuronal contamination”. To determine if higher levelsA
B
Figure 6 Correlation of BTRC mRNA and REST signature gene levels. (
plotted for 2 non-neoplastic and 200 GBM tissue samples from the cancer
A strong correlation between REST function and BTRC mRNA levels is conf
test p-value (p<10-17). (B) Scatter plot of data in (A). Statistical analyses wer
wisc.edu/mstat/).of neurons are present in near-normal glioma tumor sam-
ples with respect to REM tumors, we first had to identify
genes selectively expressed in neurons that are not likely
REST target genes. These genes were selected from a gene
expression dataset comparing fluorescently sorted neurons,
astrocytes, and glia from the murine CNS [16]. First, we
identified those genes that are most highly and selectively
expressed in neurons. Then we filtered out any genes that
had been identified as a potential REST target in published
ChIP-ChIP or ChIP-Seq experiments, or contained a
consensus 21bp REST binding element [3,17]. Figure 4A
validates the resulting 6 genes that are not REST targets as
neuron specific.
Evaluation of neuronal non-REST target genes found
that there was no concerted up-regulation of all neu-
ronal non-REST markers in either REM or near-normal
tumors. Similarly, Vascular endothelial markers VEGFR
and VE-Cadherin were not enriched in REM tumors
(data not shown) Thus we conclude that different levels ofA) Mean normalized REST signature gene and BTRC mRNA levels are
genome atlas’ (TCGA) unified and scaled gene expression dataset [21].
irmed to be statistically significant using the Kendall’s rank correlation
e performed using the Mstat software package (http://www.mcardle.
AB
Figure 7 (See legend on next page.)
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Figure 7 Consensus clustering identifies 3 distinct REST subgroups. Consensus clustering performed 1,000 iterations of delimiting TCGA
tumors (X and Y axes) into 2, 3, 4 and 5 subtypes along a spectrum of REST function. (A) Dark red pixels represent a tumor that is consistently
placed in the same group throughout the 1,000 iterations, while lighter pink pixels represent inconsistent cluster placement for tumors.
(B) Expression of REST signature genes is significantly lower in the mid-range and REM tumor groups. *p<0.05 when compared to near-normal
tumors, **p<0.05 compared to mid-range tumors, ***p<0.05 compared to both near-normal and mid-range tumors. Statistical analysis performed
using one-way ANOVA Kruskal-Wallice test and Dunn’s multiple comparisons test in Graphpad Prism 5.01.
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responsible for the observed variation in REST function
(Figure 4B and C).
In trying to determine a possible molecular cause for the
enhanced REST function, we first examined the likelihood
that it was due to altered levels of REST expression. The
gene encoding REST is located in chromosome 4q12, a re-
gion of frequent focal amplification in aggressive glioblast-
omas. Analysis of publicly available copy number data for
141 glioma tumors, however, found that the amplification
of 4q12 was centered around PDGFRA, a known glioma
oncogene (Figure 5) [18] and not around REST. In these
samples, PDGFRA was the target of frequent focal amplifi-
cation, often without the coincident amplification of REST,
which is located 2,500kb downstream (Figure 5). We next
asked if the enhanced REST function was due to increased
REST mRNA. Although Conti et al found a two- to five-
fold increase in REST mRNA between normal and malig-
nant tissue, we found no increase in REST mRNA levels in
glioma tumors, or correlation between REST mRNA levels
and REST target gene expression in the datasets we exa-
mined (data not shown). The basis for this discrepancy is
not clear. However given the poor correlation between
REST transcript levels and protein levels in gliomas [12], it
is possible that our meta-analysis picks up a different,
though perhaps overlapping group of tumors than those
described in Conti et al [11]. Thus the signature approach
would identify glioblatomas that had increased REST
function or protein levels in the absence of changes in
mRNA levels.
Given that heightened REST function is not due to
enhanced REST copy number or gene expression, we inves-
tigated possible post-transcriptional mechanisms of regula-
ting REST function. In development, REST function is
modulated in multiple ways. In neuronal stem cells, loss of
REST function is necessary for differentiation into neurons
[19]. But before REST is lost at the mRNA level in differen-
tiating neural stem cells, its function is ablated through the
expression of the the F-box protein β-TrCP, an E3 ubiquitin
ligase [5,20]. β -TrCP ubiquitinates REST, resulting in its
degradation and the de-repression of REST target genes.
We posited that β-TrCP levels maybe similarly regulating
REST function in these gliomas. Analysis of gene expres-
sion levels in normal and neoplastic brain tissues revealed
a striking correlation between the expression of REST
target genes and β -TrCP (Figure 6) (p<10-17) [21]. Thiscorrelation is consistent with the hypothesis that loss of
β-TrCP expression at the mRNA level plays a role in
enhancing REST function by reducing the levels of REST
ubiquitination and degradation.
Despite their universally poor prognosis, glioblastoma
multiformae tumors are quite heterogeneous at the mo-
lecular level. Recently, the array of recognized molecular
subtypes of GBM has expanded to include neural, pro-
neural, mesenchymal, and classical subtypes [21]. These
subtypes represent not only a different gene expression
profile, but also unique responses to treatment and a sub-
type specific enrichment in mutations and copy number
aberrations. We next sought to determine if any of these
established molecular subtypes segregated with the
enhanced REST function observed in a subset of gliomas.
In order to compare the overlap between the groups of
molecular subtypes, we first had to divide the tumors into
robust and reproducible groups delimited by REST func-
tion. To accomplish this, we made use of consensus clus-
tering, an objective method for dividing tumors into
reproducible subgroups according to their expression of a
geneset. To divide outcome-associated tumors from the
cancer genome atlas database along the lines of functional
REST levels we applied consensus clustering to the REST
gene signature, and 379 other genes that showed a very
tight correlation (p<10-8, Pavlidis Template Matching)
with REST function [22]. Using this approach, we deter-
mined that the TCGA GBM dataset was best divided into
three robust and reproducible groups (Figure 7A). These 3
groups displayed different levels of REST target gene ex-
pression and could thus be divided into REST enhanced
malignancies (REM), tumors with near-normal expres-
sion of REST targets (Near-normal), and tumors with
mid-range REST target gene expression (Mid-range)
(Figure 7B). When we compared tumor classifications we
found that each of the REST-defined subtypes was com-
prised of a heterogeneous mixture of classical, mesenc-
hymal, neural and proneural subtypes. Correspondingly,
each of the four GBM subtypes was comprised of a hetero-
geneous mix of the three REST subtypes (Figure 8). These
results suggest that these tumor groups represent distinct
clusters of molecular subtypes, each with their own unique
gene expression pattern.
The role for molecular subtypes in cancer research has
been expanding recently from helping researchers uncover
molecular mechanisms of disease to aiding clinicians and
Figure 8 Glioma subtype breakdown according to molecular classifications. Tumors from a TCGA-unified dataset delimited by molecular
subtypes and REST activity levels were tested for any overlap. Tumors with a mid-range REST activity level are predominantly proneural, while
classical and mesenchymal gliomas subtypes are classified mostly as REST enhanced malignancies.
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ment [23,24]. We sought to determine whether heightened
REST function would similarly result in increased disease
aggression [25]. To accomplish this, we assessed REST sta-
tus in an outcome-associated dataset of high-grade gliomas
(GSE4271 - grades III and IV) [26]. Upon stratification of
the tumors into REM, near-normal, and mid-range REST
functional groups, the patients with REM tumors showed a
significantly more aggressive disease course than patients
with non-REM tumors (Figure 9). These data suggest that
increased REST function may be associated with more
aggressive disease and coincide with mouse xenograft data
showing reduced survival of mice injected with “High
REST” glioma cells versus “Low REST” glioma cells [12].Figure 9 REM gliomas are more aggressive than their near-
normal counterparts. REM tumors from high-grade glioma
outcome-associated dataset GSE4271 are significantly more
aggressive than their non-REM counterparts (logrank p<0.05).
Median survivals for patients with REM (n=49) and non-REM tumors
(n=29) were 77 weeks and 148 weeks, respectively. Mid-range
(n=23) and near-normal (n=5) tumor groups were combined to add
weight to the statistical analysis.Though the most aggressive grade IV GBM tumors are
near-universally lethal, individual patient response to treat-
ment is quite varied, making the decision to undergo high-
dose chemotherapy over low-dose chemotherapy a difficult
one [21]. To determine the susceptibility of each REST
tumor subtype to high-dose chemotherapy, we compared
outcome and treatment profiles for 200 tumors from the
TCGA dataset. For patients with tumors expressing REST
target genes at near-normal and mid-range levels, the
administration of four or more rounds of chemotherapy is
associated with a statistically significant increase in disease
free survival over patients who underwent three or fewer
doses of chemotherapy (Figure 10, logrank p<0.02, p<0.01,
respectively). For patients with REM tumors, however, the
increase in survival time associated with high-dose chemo-
therapy was not statistically significant (p=0.262).
To uncover possible mechanisms behind the differential
disease course and response to treatment observed in REM
tumors we searched for glioma-associated tumor suppres-
sor genes whose mRNA expression levels co-varied with
REST signature genes (Table 1). Of the identified glioma
tumor suppressor genes, four had conserved REST binding
sites (RE1 sites): neurofibromin 1 (NF1), brain expressed
X-linked 1 (BEX1), cyclin dependent kinase inhibitor 1B
(p27KIP1) and miR-124. NF1 is a Ras GTPase activating
protein and its function is known to be lost in gliomas
through mutation or degradation [28,29]. Recently pub-
lished ChIP-ChIP data examining REST bound genes in
glial cells found that REST directly binds NF1 endoge-
nously in mouse oligodendrocytes, suggesting that NF1 is a
direct target of REST repression [17]. Our work suggests
that aberrant repression by REST may be another route to
loss of NF1 in gliomas.
BEX1 is a glioma tumor suppressor gene, the overex-
pression of which effectively suppresses human glioma
Days
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Figure 10 Tumors with Near-normal and mid-range REST activity levels, show a significant survival benefit from additional
chemotherapy. GBM tumors from the TCGA dataset are associated with both outcome and treatment information. Here, we see that additional
chemotherapy (4 or more cycles) is associated with significantly increased survival in near-normal and mid-range REST level tumors, but not REM
tumors (logrank p<0.02, p<0.01, p=0.262 respectively).
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expression is lost many gliomas, in part through promoter
methylation [30]. Published ChIP-Seq analysis for REST
bound genes found that REST directly binds the BEX1 gene
in Jurkat T-cells, suggesting that it too is an endogenous
REST target [3]. BEX1 mRNA shows a strong correlation
with REST signature gene expression (p<10-16) and is two-
fold lower in REM tumors than near-normal tumors, sug-
gesting that the reduced BEX1 expression observed in these
tumors may be due to increased REST function.
p27KIP1 is a cyclin dependent kinase inhibitor that regu-
lates the G1/S transition by inhibiting a number of CDK
complexes, including CDK2 and CDK4 [31]. Decreased ex-
pression of p27KIP1 in astrocytomas is associated with
increased proliferation, and decreased patient survival
[31,32]. p27KIP1 mRNA levels in tumors correlate with
REST signature gene expression (p<10-9) and its gene con-
tains a consensus REST binding site, suggesting that the
reduced p27KIP1 expression observed in these tumors may
be due to increased REST function.Table 1 Glioma tumor suppressors [Roopra]





REST ChIP Data are cited from either Abrajano et al (2009), Johnson et al (2007) orInterestingly, loss of NF1, p27KIP1 and BEX1 are all asso-
ciated with glioma chemotherapy resistance [30,31,33,34],
suggesting that these genes may play a role in the
reduced benefit of high dose chemotherapy in patients
with REM tumors.
Here, we have provided evidence that REST function is
increased in glioma tumors and that this heightened
activity correlates with differential tumor aggressiveness
and response to treatment. Our findings suggest a me-
chanism by which REST function may be enhanced in gli-
omas via loss of β-TrCP expression.
Importantly, we show that a decrease in a specific suite of
REST target genes correlates with failure to respond to




Transcriptional analyses on the microarray data were
performed using BRB-ArrayTools v3.7 (developed byChiP Summary
Abrajano RasGAP tumorsuppressor. Loss of NF1 by mutation
or degradation occurs in many gliomas and is
associated with chemotherapy resistance
Johnson Suppresses growth of glioma xenografts,
reintroduction of BEX1 in glioma cell lines
induces chemotherapy sensitivity
- Glioma tumor suppressor known to regulate cell growth,
apaptosis and sensitivity to chemotherapy
Conaco Glioma tumor suppressor that regulates proliferation
and differentiation
Conaro et al (2006) [27].
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Team) and MultiExperiment Viewer 4.5.1. Tumor
gene expression data were obtained from the NCBI
Gene Expression Omnibus, and are identified by their
GEO dataset record number, with the exception of the can-
cer genome atlas (TCGA) dataset, which was not available
on GEO at the time of manuscript submission. TCGA data-
sets are described [21]. Hierarchical clustering was per-
formed using a one-minus correlation metric with average
linkage over centered genes. Cluster diagrams were pro-
duced using BRB Arraytools, Cluster 3.0 and TreeView
software.
Consensus clustering
The consensus clustering method was used to deter-
mine how many REST-activity delimited glioma sub-
groups may be reproducibly established in an unbiased
fashion. First, genes that showed a high correlation of
expression with the REST 24-gene signature at p<10-8
were defined using Pavlidis Template Matching using
the MultiExperiment Viewer platform using the 200
tumor TCGA dataset. From this, 403 genes were iden-
tified and subjected to Consensus Clustering, which
was performed using BRB array tools. One thousand
iterations were used to classify tumors into 2, 3, 4 and
5 REST subtypes. In subsequent analyses, this analysis
was used to classify tumors into just 3 REST-activity
based subtypes.
Gene set enrichment analysis
Gene Set Enrichment Analysis (GSEA) was performed
using the GSEA program provided by the Broad Institute.
The list of genes identified as likely REST targets were iden-
tified in Johnson et al. using ChIP-Seq with an anti-REST
antibody. Genes were determined to be likely REST targets
based on their ChIP-Seq enrichment in two independent
experiments in a region carrying an RE1 site with a
p-value of < 10-4.
Kaplan-Meier analysis
Patient survival curves were generated using PRISM and
MSTAT software (http://www.mcardle.wisc.edu/mstat/).
Molecular classification comparison
Molecular classification of glioma tumors into classical,
mesenchymal, proneural and neural subtype information
for the TCGA tumor samples was published in Verhaak
et al 2010. To determine if tumor stratification by REST
activity level overlapped significantly with established
molecular classifications, these same tumors were re-
classified using the consensus clustering method described
above and co-incidence of classification is indicated both
with respect to published molecular subtype (top) and
REST activity level (bottom).Copy number analysis
Copy number analysis was performed using integrative gen-
omics viewer from the Broad Institute (IGV - http://www.
broadinstitute.org/igv/home). IGV was used to assess copy
number variations in 141 glioma tumors in dataser
GSE9635 previously published and characterized [18].
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